ArticleBMC ophthalmology2026
Personalized orbital decompression surgery for thyroid-associated orbitopathy: a comprehensive retrospective analysis of efficacy, safety, and surgical strategy.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to comprehensively evaluate the efficacy and safety of personalized multimodal orbital decompression for thyroid-associated orbitopathy (TAO) via large-scale retrospective analysis, and to optimize surgical strategies accordingly.
methodsA retrospective cohort study included 199 TAO patients (263 eyes) who underwent orbital decompression between September 2021 and June 2025. Patients were stratified into four groups by surgical modality: transconjunctival fat decompression, endoscopic transnasal medial wall decompression, combined transconjunctival medial-lateral wall decompression, and combined endoscopic transnasal medial-lateral wall decompression. Primary outcomes were changes in LogMAR best-corrected visual acuity (BCVA), proptosis, and intraocular pressure (IOP); secondary outcomes included ocular motility, diplopia, and postoperative complication rates.
resultsAll surgical strategies resulted in significant clinical improvements. Overall mean proptosis was reduced from 21.16 ± 2.75 mm to 15.01 ± 1.86 mm (p < 0.0001). Mean BCVA improved from 0.67 ± 0.68 LogMAR to 0.34 ± 0.42 LogMAR (p < 0.0001), with the most significant improvement seen in patients with preoperative Dysthyroid Optic Neuropathy (DON). DON was present in 46.4% of eyes, with the highest prevalence in Groups 2 (76.6%) and 4 (62.2%). Combined bony wall decompression (Groups 3 & 4) yielded the greatest proptosis reduction (7.67 mm and 7.29 mm, respectively), significantly more than single-modality decompression (p < 0.0001). The overall complication rate was 9.1%, with new-onset or worsening diplopia being the most common, but often transient or successfully managed with subsequent strabismus surgery. Endoscopic medial wall decompression (Group 2) was associated with the lowest complication rate (4.3%).
conclusionIn this large single-centre retrospective cohort, individualized orbital decompression was associated with significant improvements in proptosis, visual function, IOP, ocular motility, and diplopia-related outcomes in patients with TAO. Combined medial-lateral wall decompression achieved greater proptosis reduction, whereas procedures involving medial wall decompression were associated with visual improvement in eyes with DON. These findings support an indication-driven approach to surgical selection, while the retrospective design, baseline differences among groups, and eye-level analysis should be considered when interpreting comparative results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.